🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 11 Jul 2026 · ClinicalTrials.gov

Clinical Trials in London

← All UK trials

The most recently updated industry-sponsored clinical trials recruiting across the United Kingdom — searchable by condition, sponsor, phase and city. Refreshed daily from the ClinicalTrials.gov registry.

82
Recruiting now
118
Studies tracked
London
Selected city
Recruiting Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-03-16
📍 Truro · London · Nottingham · Taunton · Birmingham
NCT06841354 on ClinicalTrials.gov ↗
Active
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
Aortic Aneurysm, Abdominal
Shape Memory Medical, Inc. · started 2024-04-05
📍 London
NCT06029660 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd. · started 2026-03-27
📍 Leicester · London
NCT07440225 on ClinicalTrials.gov ↗
Recruiting Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca · started 2020-06-03
📍 Cambridge · Dundee · London · Manchester · Sutton
NCT04379596 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH · started 2025-02-19
📍 Leeds · London · Manchester
NCT06980805 on ClinicalTrials.gov ↗
Active Phase 3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Biliary Tract Cancer
AstraZeneca · started 2023-12-04
📍 Cambridge · Edgbaston · Glasgow, Scotland · London · Manchester
NCT06109779 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-07-21
📍 London · Leicester · Manchester
NCT07060807 on ClinicalTrials.gov ↗
Active Phase 3
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
Sickle Cell Disease (SCD)
Novartis Pharmaceuticals · started 2019-07-26
📍 Sheffield · Cambridge · London
NCT03814746 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Immunovant Sciences GmbH · started 2025-06-19
📍 Cornwell · London · Merthyr Tydfil · Salford · Surrey
NCT07018323 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals · started 2024-10-09
📍 Basingstoke · Bristol · London
NCT06470048 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2025-10-08
📍 Truro · London · Birmingham · Leicester
NCT07190248 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC · started 2023-12-13
📍 Bristol · Lancaster · London · Oxford · Newmarket
NCT06136559 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves' Disease
Immunovant Sciences GmbH · started 2024-12-17
📍 Birmingham · Bristol · Coventry · London · Cambridge
NCT06727604 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
Dyne Therapeutics · started 2026-05-14
📍 London
NCT07486934 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Neoplasms
Celgene · started 2018-07-19
📍 Leeds · London · Manchester Withington · Shirley Southampton
NCT03435796 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC · started 2025-04-09
📍 Cambridge · Edinburgh · London · Sutton · Leicester
NCT06824467 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA · started 2022-06-21
📍 Cambridge · Liverpool · London · Oxford · Warrington
NCT05462106 on ClinicalTrials.gov ↗
Recruiting Phase 1
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
Hepatocellular Carcinoma
Bayer · started 2025-02-28
📍 London · Glasgow · Sutton
NCT06764316 on ClinicalTrials.gov ↗
Active Phase 3
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
Hypereosinophilic Syndrome
AstraZeneca · started 2020-07-20
📍 London
NCT04191304 on ClinicalTrials.gov ↗
Active Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca · started 2020-08-18
📍 London · Manchester · Sutton
NCT04482309 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda · started 2025-08-14
📍 Leicester · Southampton · Southwark · Liverpool · Glasgow
NCT06948318 on ClinicalTrials.gov ↗
Active Phase 2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Metastatic Breast Cancer
Merck Sharp & Dohme LLC · started 2024-11-27
📍 Truro · London · Withington · Ipswich
NCT06428396 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC · started 2025-07-20
📍 Edinburgh · Glasgow · London · Cardiff · Manchester
NCT07049926 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Immune Thrombocytopenic Purpura (ITP)
Takeda · started 2025-02-27
📍 Leicester · Southampton · Southwark · Liverpool · Glasgow
NCT06722235 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC · started 2024-04-14
📍 Londonderry · Truro · London · Blackpool · Nottingham
NCT06312176 on ClinicalTrials.gov ↗
Active Phase 3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche · started 2021-10-27
📍 Cornwall · Gloucester · London · Nottingham · Torquay
NCT04712097 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC · started 2024-12-20
📍 London
NCT06637423 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines · started 2026-01-22
📍 Bournemouth · London
NCT07277231 on ClinicalTrials.gov ↗
Recruiting Phase 2
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc. · started 2026-06-30
📍 Liverpool · London · Manchester
NCT07523581 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Non Small Cell Lung Cancer
Merck Sharp & Dohme LLC · started 2024-04-03
📍 Cambridge · Northwood · London · Oxford · Newcastle upon Tyne
NCT06312137 on ClinicalTrials.gov ↗
Active Phase 1
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Metastatic Neuroendocrine Prostate Cancer
Novartis Pharmaceuticals · started 2024-07-29
📍 Sutton · London
NCT06379217 on ClinicalTrials.gov ↗
Recruiting Phase 3
Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence
Fecal Incontinence
Innovacell GmbH · started 2022-05-11
📍 London
NCT04976153 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
AstraZeneca · started 2025-07-17
📍 Bristol · Dundee · Headington · London · Norwich
NCT07069712 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-06-27
📍 London · Manchester
NCT06998524 on ClinicalTrials.gov ↗
Recruiting Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen · started 2025-07-31
📍 London · Sutton
NCT07094113 on ClinicalTrials.gov ↗
Active Phase 3
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals · started 2021-07-27
📍 Leeds · London
NCT04747613 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Colon Adenocarcinoma, Rectal Adenocarcinoma
Merck Sharp & Dohme LLC · started 2025-07-16
📍 Birmingham · London · Oxford · Coventry · Manchester
NCT06997497 on ClinicalTrials.gov ↗
Recruiting Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Von Hippel-Lindau Disease, Malignant Neoplasms
Merck Sharp & Dohme LLC · started 2026-03-23
📍 Glasgow · London · Manchester
NCT07405164 on ClinicalTrials.gov ↗
Active
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V. · started 2023-04-25
📍 Brighton · Lincoln · London · Londonderry · Newcastle
NCT05705973 on ClinicalTrials.gov ↗
Active Phase 3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Cancer
Hoffmann-La Roche · started 2017-09-20
📍 London · Manchester · Metropolitan Borough of Wirral · Nottingham · Surrey
NCT03148418 on ClinicalTrials.gov ↗
Starting soon Phase 2
A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
Refractory Chronic Cough and Unexplained Chronic Cough
Sensory Cloud, Inc. · started 2026-06-15
📍 Belfast · London
NCT07690059 on ClinicalTrials.gov ↗
Active
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Von Willebrand Disease, Type 3
Hoffmann-La Roche · started 2025-04-29
📍 London · Manchester
NCT06883240 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Dermatitis Atopic
Sanofi · started 2024-05-08
📍 Portsmouth · Leicester · London · Glasgow
NCT06407934 on ClinicalTrials.gov ↗
Recruiting Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC · started 2024-06-10
📍 Londonderry · Torquay · London · Nottingham
NCT06422143 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC · started 2025-06-30
📍 London · Dundee · Huddersfield · Colchester · Orpington
NCT06966700 on ClinicalTrials.gov ↗
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
Aortic Stenosis
Abbott Medical Devices · started 2023-09-29
📍 London · Middlesbrough · Stoke-on-Trent · Wolverhampton
NCT06008080 on ClinicalTrials.gov ↗
Recruiting Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Immunovant Sciences GmbH · started 2025-06-30
📍 Cambridge · Liverpool · London · Swindon · Truro
NCT06979531 on ClinicalTrials.gov ↗
Recruiting Phase 2
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Type 1 Diabetes
SAb Biotherapeutics, Inc. · started 2025-11-25
📍 Cambridge · Cardiff · Edinburgh · Liverpool · London
NCT07187531 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Regeneron Pharmaceuticals · started 2024-10-30
📍 Liverpool · York · Bristol · London · Newcastle upon Tyne
NCT06541704 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy Secondary to Age-related Macular Degeneration
Novartis Pharmaceuticals · started 2026-03-09
📍 Bristol · London
NCT07441642 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim · started 2025-09-13
📍 Antrim · Bath · Birmingham · Leeds · London
NCT06806592 on ClinicalTrials.gov ↗
Starting soon Phase 3
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
AstraZeneca · started 2026-09-01
📍 London · Newcastle upon Tyne · Sheffield
NCT07691970 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Boehringer Ingelheim · started 2026-02-10
📍 Exeter · London
NCT07201922 on ClinicalTrials.gov ↗
Active Phase 3
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Zealand Pharma · started 2019-05-02
📍 Glasgow · Liverpool · London · Manchester
NCT03941236 on ClinicalTrials.gov ↗
Active Phase 3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
CLL
BeOne Medicines · started 2023-11-11
📍 Bournemouth · Canterbury · Headington · Leeds · Liverpool
NCT06073821 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Heart Failure
Novo Nordisk A/S · started 2025-06-27
📍 Birmingham · High Wycombe · London · Middlesbrough · Southampton
NCT06979362 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Chronic Kidney Disease
Boehringer Ingelheim · started 2025-12-09
📍 Birmingham · Bristol · Glasgow · Liverpool · London
NCT07107945 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
HER2-positive Breast Cancer
Hoffmann-La Roche · started 2026-05-21
📍 Leicester · London · Manchester · Sutton
NCT07413939 on ClinicalTrials.gov ↗
Recruiting Phase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Macular Edema
Boehringer Ingelheim · started 2025-06-05
📍 Camberley · Gloucester · Harrow · Liverpool · London
NCT06962839 on ClinicalTrials.gov ↗
Recruiting Phase 2
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
Osteogenesis Imperfecta (OI)
Angitia Incorporated Limited · started 2025-12-12
📍 Cambridge · Edinburgh · London · Oxford
NCT07062588 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Chronic Kidney Disease
Boehringer Ingelheim · started 2025-07-18
📍 Airdrie · Glasgow · Harrow · High Wycombe · London
NCT06926660 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes
Bayer · started 2022-10-14
📍 London · Liverpool · Glasgow · Redhill · Aberdeen
NCT05587296 on ClinicalTrials.gov ↗
Recruiting Phase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Muscular Atrophy, Spinal
Hoffmann-La Roche · started 2024-08-14
📍 London
NCT05861999 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
Dravet Syndrome
Encoded Therapeutics · started 2024-05-14
📍 Glasgow · London
NCT05419492 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi · started 2025-08-06
📍 Cambridge · Dundee · London · Glasgow · Bath
NCT07088068 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics · started 2025-01-28
📍 Aberdeen · Birmingham · Cambridge · Glasgow · Leeds
NCT06788990 on ClinicalTrials.gov ↗
Active Phase 3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer · started 2014-12-17
📍 Glasgow · Wonford · London · Sutton · Birmingham
NCT02319837 on ClinicalTrials.gov ↗
Recruiting Phase 3
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
AstraZeneca · started 2026-05-05
📍 Edinburgh · Hampshire · Leeds · London · Manchester
NCT07509151 on ClinicalTrials.gov ↗
Active Phase 2
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea · started 2024-12-11
📍 Headington · Edinburgh · London
NCT06627179 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim · started 2024-06-17
📍 Barnet · Bristol · Exeter · Halifax · High Wycombe
NCT06424288 on ClinicalTrials.gov ↗
Recruiting Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim · started 2026-01-16
📍 Cardiff · Edinburgh · London · Manchester · Sutton
NCT07195695 on ClinicalTrials.gov ↗
Active Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Gastric Cancer, Gastroesophageal Junction Cancer
AstraZeneca · started 2024-03-04
📍 Cambridge · London · Manchester · Oxford · Taunton
NCT06346392 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC · started 2021-05-12
📍 Cambridge · Glasgow · London · Newcastle upon Tyne · Sheffield
NCT07218029 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder, NMOSD
Hoffmann-La Roche · started 2026-05-06
📍 London
NCT05199688 on ClinicalTrials.gov ↗
Recruiting Phase 1
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
Nuvectis Pharma, Inc. · started 2023-10-26
📍 Edinburgh · London
NCT05873686 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines · started 2021-09-16
📍 Headington · London · Sutton · Truro
NCT04973605 on ClinicalTrials.gov ↗
Recruiting Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer · started 2025-09-28
📍 Blackburn · Cardiff · Plymouth · Torquay · London
NCT07028853 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Mirati Therapeutics Inc. · started 2020-12-02
📍 Birmingham · Edinburgh · Kent · Leicester · London
NCT04613596 on ClinicalTrials.gov ↗
Recruiting Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric Migraine
Pfizer · started 2021-01-15
📍 Leicester · London
NCT04649242 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor
Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
Regeneron Pharmaceuticals · started 2026-02-11
📍 Leeds · London
NCT07187401 on ClinicalTrials.gov ↗
Recruiting Phase 2
Rescue of Nephrons With ALE.F02 (RENAL-F02)
Glomerulonephritis Rapidly Progressive
Alentis Therapeutics AG · started 2023-09-07
📍 Birmingham · Cambridge · Liverpool · London · Manchester
NCT06047171 on ClinicalTrials.gov ↗
Active Phase 1
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Boehringer Ingelheim · started 2021-07-02
📍 London · Sutton
NCT04886804 on ClinicalTrials.gov ↗
Recruiting Phase 2
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
Satellos Bioscience, Inc. · started 2025-12-08
📍 London
NCT07287189 on ClinicalTrials.gov ↗
Active Phase 2/Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Generalized Epidermolysis Bullosa Simplex
TWi Biotechnology, Inc. · started 2024-04-04
📍 London
NCT06073132 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Menstrual Migraine
Pfizer · started 2025-03-11
📍 Bristol · Milton Keynes · Hull · London · Fazakerley
NCT06641466 on ClinicalTrials.gov ↗
Recruiting Phase 2
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim · started 2023-10-13
📍 Leicester · London · Manchester · Newcastle upon Tyne
NCT05882058 on ClinicalTrials.gov ↗
Active Phase 2
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Solid Tumours
Boehringer Ingelheim · started 2024-12-30
📍 Cambridge · London
NCT06619509 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
CLL, Chronic Lymphocytic Leukemia
BeOne Medicines · started 2025-04-10
📍 Aberdeen · Birmingham · Bournemouth · London · Southampton
NCT06846671 on ClinicalTrials.gov ↗
Recruiting Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer · started 2024-02-08
📍 Milton Keynes · Bodelwyddan · Bournemouth · Poole · Eastbourne
NCT06152575 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis · started 2025-07-21
📍 Liverpool · London · Oxford · Sheffield · Swansea
NCT06943755 on ClinicalTrials.gov ↗
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc · started 2023-12-27
📍 London · Oxford · Southhampton
NCT06059638 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer · started 2025-10-03
📍 Cambridge · London · Liverpool
NCT06989437 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim · started 2024-05-06
📍 Aberdeen · Birmingham · Bristol · Edinburgh · Exeter
NCT06238622 on ClinicalTrials.gov ↗
Active Phase 3
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals · started 2022-12-19
📍 London · Newcastle upon Tyne
NCT05335876 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim · started 2025-05-20
📍 Bristol · Clydebank · Exeter · Halifax · Harrow
NCT06935370 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim · started 2024-06-03
📍 Cardiff · Leeds · London · Manchester · Newcastle upon Tyne
NCT06324357 on ClinicalTrials.gov ↗
Active Phase 3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Pfizer · started 2019-09-05
📍 Yeovil · London
NCT03950232 on ClinicalTrials.gov ↗
Recruiting Phase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
Recurrent Pericarditis, Heart Diseases, Pericarditis
Kiniksa Pharmaceuticals International, plc · started 2026-03-25
📍 London
NCT07288216 on ClinicalTrials.gov ↗
Recruiting Phase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Healthy
Pfizer · started 2025-08-25
📍 Bristol · London · Manchester · Truro · Southampton
NCT07160244 on ClinicalTrials.gov ↗
Starting soon Phase 2
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · started 2026-08-31
📍 London · Sheffield
NCT07603557 on ClinicalTrials.gov ↗
Recruiting
Abbott Structural Heart Device Registry
Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices · started 2024-08-21
📍 London
NCT06590467 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
AbbVie · started 2025-12-10
📍 London · Manchester
NCT07155187 on ClinicalTrials.gov ↗
By invitation
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Obesity
Novo Nordisk A/S · started 2025-05-01
📍 West Bromwich · Barnsley · Hull · London · Luton
NCT07055607 on ClinicalTrials.gov ↗
Active Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Follicular Lymphoma (FL)
Genmab · started 2022-09-20
📍 Plymouth · Glasgow · London · Oxford · Leeds
NCT05409066 on ClinicalTrials.gov ↗
Active
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
Spasticity as Sequela of Stroke
Ipsen · started 2023-11-01
📍 Leicester · Liverpool · London · Middlesbrough · Nottingham
NCT06055725 on ClinicalTrials.gov ↗
Active Phase 3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Myelofibrosis
Geron Corporation · started 2021-04-12
📍 London · Oxford
NCT04576156 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Lichen Planopilaris
Priovant Therapeutics, Inc. · started 2026-03-19
📍 Salford · Glasgow · Brighton · London · Wrexham
NCT07532603 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc. · started 2024-03-13
📍 High Wycombe · Bristol · Glasgow · Hull · London
NCT06318169 on ClinicalTrials.gov ↗
By invitation Phase 3
An Open-label Study of XEN1101 in Epilepsy
Focal Epilepsy, Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc. · started 2023-04-25
📍 Leeds · Cardiff · Birmingham · London · Oxford
NCT05718817 on ClinicalTrials.gov ↗
Recruiting Phase 1
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals · started 2026-04-24
📍 London
NCT07422610 on ClinicalTrials.gov ↗
Recruiting
The PERSEVERE Study
Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical · started 2024-12-16
📍 London
NCT06588634 on ClinicalTrials.gov ↗
Recruiting Phase 1
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd · started 2026-07
📍 Cambridge · Edinburgh · Glasgow · Leeds · Leicester
NCT07665515 on ClinicalTrials.gov ↗
Active Phase 3
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NASH, Cirrhosis, Liver
Madrigal Pharmaceuticals, Inc. · started 2022-08-26
📍 Birmingham · Cambridge · London
NCT05500222 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines · started 2025-06-11
📍 Bournemouth · Leeds · London · Metropolitan Borough of Wirral · Newcastle upon Tyne
NCT06943872 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio · started 2023-12-20
📍 London · Manchester · Salford
NCT06154252 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc. · started 2024-09-27
📍 Truro · Brighton · London · Cheltenham · Northwood
NCT06492616 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Duchenne Muscular Dystrophy
Solid Biosciences Inc. · started 2024-05-06
📍 London
NCT06138639 on ClinicalTrials.gov ↗
Active Phase 2
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
Hepatitis B
GlaxoSmithKline · started 2024-09-17
📍 Bristol Avon · London
NCT06497504 on ClinicalTrials.gov ↗
No trials match your search.

Browse by city

London · 118 Manchester · 30 Glasgow · 27 Cambridge · 27 Birmingham · 24 Leicester · 23 Bristol · 23 Leeds · 22 Sutton · 19 Oxford · 19 Liverpool · 18 Edinburgh · 15 Nottingham · 14 Cardiff · 14 Newcastle upon Tyne · 13 Sheffield · 12

Browse by condition

Obesity · 5 Chronic Lymphocytic Leukemia · 5 Cancer · 4 Breast Neoplasms · 3 Non-small Cell Lung Cancer · 3 Small Lymphocytic Lymphoma · 3 Multiple Myeloma · 3 Hypertension · 3 Heart Failure · 3 Triple Negative Breast Neoplasms · 2 Lymphoma, Non-Hodgkin · 2 Lymphoma, Follicular · 2 Lymphoma, Large B-Cell, Diffuse · 2 Gastric Cancer · 2 Metastatic Prostate Cancer · 2 Overweight · 2
Cite this page

Priya Life Science (2026). Clinical Trials in the UK Tracker. Available at: https://priyalifescience.com/clinical-trials-uk/city/london (Accessed: 11 July 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — industry-sponsored studies in a recruiting status with at least one UK site, most recently updated first, refreshed daily. This is a curated slice of the registry, not every UK trial; UK studies may also be registered on ISRCTN. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician. Compare pay for the teams running these studies in our UK Pharma Salary Guide, or see our Ireland, EU and USA trackers.